Data rooms tell you what a business looks like. They rarely tell you what a business is about to face. When a mid-market private equity fund began evaluating a diagnostic services chain operating across four Indian states, the financial picture was clean and the management team was credible. What nobody in the room could answer was whether the conditions that made the business attractive would still exist three years into the hold period.
That is the question that brought them to Nextyn.
The fund had built its investment thesis around two assumptions. The first was that reimbursement rates under Ayushman Bharat, India's national health assurance scheme, would remain stable across the five-year hold period. The second was that the competitive position in the tier-two cities where the target operated most of its facilities was as durable as the management presentation suggested.
Neither assumption could be stress-tested using publicly available information. The policy documents explained how Ayushman Bharat worked. They said nothing about where the rates were heading. The industry reports described the competitive landscape as it existed twelve to eighteen months earlier. None of it could answer the question that actually mattered: what is happening in these specific markets right now, as seen by the people operating inside them?
Nextyn was engaged to source practitioners with direct, current experience in India's diagnostic services sector, specifically in the geographies the target operated in. The brief was precise. The fund needed people who could speak to reimbursement policy implementation at the state level, competitive dynamics in tier-two diagnostic markets, and the operational realities of running a network heavily dependent on government scheme revenue.
Over eight days, Nextyn sourced and facilitated conversations with seven practitioners. Two were former senior officials from the state health departments in the relevant states, each with direct involvement in implementing Ayushman Bharat at the operational level. Three were former executives from competing diagnostic chains who had run businesses in the same tier-two city markets. Two were healthcare consultants with active mandates advising similar businesses on pricing and government relations strategy. Calls were conducted in English and Hindi according to each practitioner's preference, with moderation provided by Nextyn's team where requested.
The picture that came back from the call programme was materially different from the one in the data room, in two specific areas.
On the reimbursement question, both state health department practitioners independently described an active policy review at the ministry level covering the specific diagnostic procedures that made up the majority of the target's scheme-linked revenue. Both described the review as being driven by fiscal pressure on state governments, which are responsible for co-funding the scheme. Neither expected current rates to hold through the investment period without renegotiation. This was not a published position. It was the practitioner's view of a process that had not yet produced a single public document.
On competitive dynamics, three of the former diagnostic executives independently described accelerating capacity addition by well-funded national chains in the exact tier-two cities the target considered its most defensible markets. The same government scheme volumes underpinning the target's growth story had made those cities attractive enough for national players to prioritise. The competitive moat the management team described had been real two years earlier. It was narrowing.
The fund did not walk away. What the research produced instead was a fundamentally different framing of the risk. The reimbursement trajectory moved from a downside scenario into the base case financial model, which changed the entry valuation discussion materially. The competitive dynamics finding led the fund to include specific operational milestones in the investment structure, tied to network expansion in markets where the competitive pressure was least advanced, as conditions for releasing the second tranche of capital.
When the findings were shared with the management team, they confirmed both the reimbursement review and the competitive incursion in two of the tier-two markets. The primary research had surfaced what the data room had not.
India attracts billions in private capital across its healthcare sector every year. It is also one of the most information-asymmetric investment environments in Asia. The gap between what published sources describe and what is actually happening at the sub-state level, where most healthcare businesses actually operate, is wider in India than in most comparable markets. Understanding state-level policy implementation, ground-level competitive dynamics, and the practitioner view of where the sector is heading requires access to people who are embedded in those markets. No secondary source can give you that.
